Hirakura Yutaka, Kojima Seiki, Okada Akira, Yokohama Shigeharu, Yokota Shoji
Novel Pharmaceutical Laboratories, Yamanouchi Pharmaceutical Co. Ltd., 180 Ozumi, Yaizu, Shizuoka 425-0072, Japan.
Int J Pharm. 2004 Nov 22;286(1-2):53-67. doi: 10.1016/j.ijpharm.2004.07.030.
Lyophilized protein formulations sometimes pose problems such as the formation of a cloudy solution upon reconstitution. Ampoule or vial breakage can also occur during the production processes of lyophilized pharmaceutical products. Various efforts have been made to overcome those difficult problems. In this study, we introduce a particular temperature program into the production process of a recombinant human Interleukin-11 (rhIL-11) lyophilized formulation containing sodium phosphates (Na2HPO4/NaH2PO4, pH 7.0) and glycine in an attempt to improve its dissolution properties and to prevent ampoule breakage from occurring. The formulation was pretreated by nucleating ice and maintaining the solution overnight at a temperature of -6 degrees C. The solution was then completely frozen at a lower temperature. This pretreatment proved successful in not only producing a lyophilized cake which readily disintegrated and dissolved in the reconstitution media, but also prevented ampoule breakage from occurring during the production processes. In contrast, a lyophilized cake produced without the pretreatment created a cloudy solution particularly when reconstituted using water for injection contaminated with aluminum (Al3+), although the solution became transparent within 20-30 min. The pretreatment induced the crystallization of sodium dibasic phosphate (Na2HPO4) in the freeze-concentrate whereas direct freezing without the pretreatment did not crystallize the salt. Thermal analyses (DSC and TMA) showed that amorphous sodium dibasic phosphate in the freeze-concentrate became crystallized upon heating, accompanied by an increase in volume, which probably caused the ampoule breakage that occurred without the pretreatment. Although power X-ray diffraction (PXRD) experiments suggested that, with or without the pretreatment, glycine assumed the beta-form and sodium phosphate stayed amorphous in the final products, an electrostatic interaction between dibasic phosphate anions and rhIL-11, a highly cationic protein, would only exist in the lyophilized cake produced without the pretreatment. This interaction is highly likely because aluminum facilitates the formation of a cloudy solution upon reconstitution possibly by using the divalent anions which effectively reduce electrostatic repulsions between aluminum and the protein to form an aggregate structure that is not readily soluble. The pretreatment would circumvent the interaction by crystallizing the sodium salt before freezing creating a relatively soluble lyophilized cake that is much less sensitive to aluminum.
冻干蛋白质制剂有时会出现一些问题,比如复溶后形成浑浊溶液。在冻干药品的生产过程中还可能发生安瓿或小瓶破裂的情况。人们已经做出了各种努力来克服这些难题。在本研究中,我们将特定的温度程序引入到一种重组人白细胞介素-11(rhIL-11)冻干制剂的生产过程中,该制剂含有磷酸钠(Na2HPO4/NaH2PO4,pH 7.0)和甘氨酸,旨在改善其溶解性能并防止安瓿破裂。该制剂先通过冰核形成进行预处理,并在-6℃的温度下将溶液保持过夜。然后将溶液在更低温度下完全冷冻。事实证明,这种预处理不仅成功制备出了易于崩解并能在复溶介质中溶解的冻干饼,还防止了生产过程中安瓿破裂的发生。相比之下,未经预处理制备的冻干饼会产生浑浊溶液,尤其是当使用被铝(Al3+)污染的注射用水复溶时,不过溶液在20 - 30分钟内会变澄清。预处理促使磷酸氢二钠(Na2HPO)在冷冻浓缩物中结晶,而未经预处理的直接冷冻则不会使该盐结晶。热分析(DSC和TMA)表明,冷冻浓缩物中的无定形磷酸氢二钠在加热时会结晶,同时体积增加,这可能导致了未经预处理时发生的安瓿破裂。尽管粉末X射线衍射(PXRD)实验表明,无论有无预处理,甘氨酸在最终产品中呈β型,磷酸钠保持无定形,但二磷酸根阴离子与高度带正电的蛋白质rhIL-11之间的静电相互作用只会存在于未经预处理制备的冻干饼中。这种相互作用很有可能发生,因为铝可能通过利用二价阴离子促进复溶时形成浑浊溶液,这些二价阴离子有效地减少了铝与蛋白质之间的静电排斥,从而形成不易溶解的聚集体结构。预处理通过在冷冻前使钠盐结晶来规避这种相互作用,从而制备出相对易溶的冻干饼,且该冻干饼对铝的敏感性要低得多。